RXi Pharmaceuticals this week announced that it has completed patient dosing in a phase I trial of its first clinical candidate, the RNAi-based dermal scarring drug RXI-109.

The drug uses the company's so-called self-delivering RNAi technology to inhibit connective tissue growth factor, a protein linked to wound healing and other fibrotic processes.

In the dose-escalation study, 15 abdominoplasty patients received intradermal injection of RXI-109 in two separate areas on the abdomen and placebo injections on two other areas.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.